Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.90 and last traded at C$0.89, with a volume of 7074 shares traded. The stock had previously closed at C$0.89.
Aptose Biosciences Price Performance
The firm has a market capitalization of C$14.52 million, a PE ratio of -0.09 and a beta of 1.47. The firm’s 50-day moving average is C$1.24 and its 200 day moving average is C$1.92. The company has a debt-to-equity ratio of 14.27, a quick ratio of 5.41 and a current ratio of 0.78.
Aptose Biosciences (TSE:APS – Get Free Report) (NASDAQ:APTO) last released its earnings results on Tuesday, May 14th. The biotechnology company reported C($0.98) earnings per share for the quarter, topping the consensus estimate of C($1.12) by C$0.14. As a group, research analysts forecast that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- Best Stocks Under $5.00
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- High Flyers: 3 Natural Gas Stocks for March 2022
- Has This Leading Tech Stock Halted the AI Surge?
- How to Capture the Benefits of Dividend Increases
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
